The GVHD market is growing due to increasing transplant procedures and novel therapeutic developments. Key players including Incyte Corporation (Jakafi), Pfizer, and Equillium are advancing JAK inhibitors, monoclonal antibodies, and cellular therapies that improve response rates and reduce steroid dependence. Diagnostic advancements and treatment guidelines are optimizing management strategies for this serious transplant complication. Access Full Report: https://www.delveinsight.com/infographics/graft-versus-host-disease-gvhd-market?utm_source=infographics&utm_medium=promotion&utm_campaign=kkpr